The DOI matches its Crossref record; 261 of the 272 references it cites were found in a registry or an index; none of the 127 sources its claims cite is checked for support yet.
Mitochondrial DNA mutations and human disease
Open accessAbstract
Mitochondrial disorders are a group of clinically heterogeneous diseases, commonly defined by a lack of cellular energy due to oxidative phosphorylation (OXPHOS) defects. Since the identification of the first human pathological mitochondrial DNA (mtDNA) mutations in 1988, significant efforts have been spent in cataloguing the vast array of causative genetic defects of these disorders. Currently, more than 250 pathogenic mtDNA mutations have been identified. An ever-increasing number of nuclear DNA mutations are also being reported as the majority of proteins involved in mitochondrial metabolism and maintenance are nuclear-encoded. Understanding the phenotypic diversity and elucidating the molecular mechanisms at the basis of these diseases has however proved challenging. Progress has been hampered by the peculiar features of mitochondrial genetics, an inability to manipulate the mitochondrial genome, and difficulties in obtaining suitable models of disease. In this review, we will first outline the unique features of mitochondrial genetics before detailing the diseases and their genetic causes, focusing specifically on primary mtDNA genetic defects. The functional consequences of mtDNA mutations that have been characterised to date will also be discussed, along with current and potential future diagnostic and therapeutic advances.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes mitochondrial DNA (mtDNA) genetics, the clinical syndromes caused by primary mtDNA mutations, diagnostic approaches, experimental models, and therapeutic/prevention strategies. It emphasizes that more than 250 pathogenic mtDNA mutations are known, but heteroplasmy, threshold effects, genotype–phenotype heterogeneity, and limited disease models continue to complicate understanding and treatment.
Key findings
- Since the first pathogenic mtDNA mutations were identified in 1988, over 250 pathogenic mtDNA mutations have been characterized; the mtDNA mutation rate is 10- to 17-fold higher than nuclear DNA. Prevalence estimates from North East England suggest 1 in 10,000 people have clinically manifesting mtDNA disease and a further 1 in 6000 are at risk; mutation frequencies include 0.14% for m.3243A>G and ∼0.2% for m.1555A>G.
- Mitochondrial genetics is shaped by maternal inheritance, heteroplasmy/homoplasmy, a threshold effect typically around 60%–90% mutant mtDNA, mitotic segregation, clonal expansion, and a developmental bottleneck. Phenotype depends on mutation load and tissue, not simply on mutation size or location.
- Common syndromes and mutations include MELAS (over 80% have m.3243A>G), LHON (three primary mutations account for at least 95% of cases; 50% of males versus 10% of females develop visual loss; recovery is 71% with m.14484T>C versus 25% with m.11778G>A), NARP/MILS (m.8993T>G; mutant load greater than 95% associates with childhood MILS), MERRF (m.8344A>G), KSS/Pearson syndrome (single large-scale deletions), and CPEO.
- Diagnosis uses histochemistry (ragged red fibres, COX-deficient fibres), biochemical respiratory chain assays, and molecular testing (RFLP, long-range PCR, sequencing, microarrays). No effective treatment is currently available; exercise and gene therapy approaches are under investigation, and prevention strategies include prenatal diagnosis, preimplantation genetic diagnosis, pronuclear transfer, and spindle-chromosome transfer.
Methods
- Narrative review; no primary data, systematic search strategy, or formal inclusion criteria are described. The evidence base is published literature on mtDNA genetics, clinical syndromes, diagnosis, functional characterization, and management.
- The review synthesizes cited studies and databases, including MITOMAP, and discusses experimental models such as transmitochondrial cybrids, yeast models, and mouse models, as well as transcriptomic and proteomic investigations.
- Main analysis is qualitative synthesis, with figures for genotype–phenotype correlations and criteria for assigning pathogenicity to novel mtDNA variants.
Limitations
- The paper states that progress has been hampered by the peculiar features of mitochondrial genetics, an inability to manipulate the mitochondrial genome, and difficulties in obtaining suitable models of disease; it also notes that no effective therapies or cures are presently available and that exact prevalence is difficult to ascertain.
- The text makes evident that this is a narrative review without systematic search or primary data, and that several areas remain debated or uncertain, including the exact mechanism of mtDNA replication, the mtDNA bottleneck, and the mechanism of mtDNA deletion formation.
- Model-specific limitations are stated: cybrids often use aneuploid tumour cells and glycolytic host cells, and cybridization can alter the transcriptome; yeast are inherently homoplasmic and S. cerevisiae lack complex I; mouse mtDNA cannot be directly manipulated, requiring indirect approaches.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 127 cited sources checked · 0 supported · 0 flagged
None of the sources cited for this claim have been checked yet.
In the paper
“Although mtDNA repair systems do exist [51,52]”
§ Review Mitochondrial DNA mutations and human disease > 3. Clinical features of human mtDNA disease
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The mitochondrial genome has a very high mutation rate, 10-to 17-fold higher than that observed in nuclear DNA.”
§ Review Mitochondrial DNA mutations and human disease > 3. Clinical features of human mtDNA disease
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“The occurrence of multiple mtDNA deletions of varying lengths in affected tissues may be due to inherited mutations in nuclear genes, whose products are involved in mtDNA maintenance and replication (e.g., POLG and PEO1 encoding Twinkle) and mitochondrial nucleotide metabolism (e.g., SLC25A4) [88][89][90].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [88][89][90]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“To complicate matters further, a dominant mt-tRNA mutation, m.5545C N T in the MT-TW gene, was recently reported with levels of mutation at b25% in clinically affected tissues [83].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.1. Point mutations
What the sources say
- Not checked yetcites [83] Sacconi, 2008, A functionally dominant mitochondrial DNA mutation, Hum. Mol. Genet. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“The observation of a rapid segregation in mammalian heteroplasmic mtDNA genotypes between generations, with a return to homoplasmy in some progeny, has suggested the existence of a mtDNA bottleneck during development [67][68][69][70][71][72].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.4. MtDNA bottleneck
What the sources say
- Not checked yetcites [67][68][69][70][71][72]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“For example, an average annual 1% decrease in m.3243A N G mutation levels in blood has been described [63].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.2. Mitotic segregation
What the sources say
- Not checked yetcites [63] Rahman, 2001, Decrease of 3243 A–>G mtDNA mutation from blood in MELAS syndrome: a longitudinal study, Am. J. Hum. Genet. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Over 80% of patients with MELAS have the m.3243A N G mutation in the MT-TL1 gene [109,110].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“In these children, there is a very high level of large-scale single mtDNA deletion present in all tissues [108].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.1.4. Pearson syndrome.
What the sources say
- Not checked yetcites [108] Rotig, 1990, Pearson's marrow–pancreas syndrome. A multisystem mitochondrial disorder in infancy, J. Clin. Invest. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“There are three primary LHON mtDNA mutations (m.11778G N A, m.3460G N A, and m.14484T N C), which in total are present in at least 95% of LHON cases [56,124].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.4. Leber's hereditary optic neuropathy (LHON).
What the sources say
- Not checked yetcites [56] MITOMAP: A Human Mitochondrial Genome Database. http://www.mitomap.org. 2009.
- Not checked yetcites [124] Man, 2002, Leber hereditary optic neuropathy, J. Med. Genet. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“It has subsequently been recognised that patients with a mutant load greater than 95% m.8993T N G have an onset in childhood with maternally inherited Leigh syndrome (MILS) [123].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.3. Neuropathy, ataxia, and retinitis pigmentosa (NARP).
What the sources say
- Not checked yetcites [123] Tatuch, 1992, Heteroplasmic mtDNA mutation (T----G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high, Am. J. Hum. Genet.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 6
- It may state two separate claims as one. 36
In the paper
“Currently, more than 250 pathogenic mtDNA mutations have been identified.”
- Also stated in: § 3. Clinical features of human mtDNA disease · plain
“Since then, over 250 pathogenic mtDNA mutations (point mutations and rearrangements) have been characterised [56]”
§ Review Mitochondrial DNA mutations and human disease > Abstract
What the sources say
- Not checked yetcites [56] MITOMAP: A Human Mitochondrial Genome Database. http://www.mitomap.org. 2009.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § 3. Clinical features of human mtDNA disease · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The onset of clinical symptoms, phenotypic variability, and variable penetrance of mitochondrial diseases are governed by a number of factors, including the threshold effect, mitotic segregation, clonal expansion, and a genetic bottleneck.”
§ Review Mitochondrial DNA mutations and human disease > 3.1. Specific features of mitochondrial disease
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
- Rests on an assumption: In heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.
- Rests on an assumption: A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.
- Rests on an assumption: The threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.
- Rests on an assumption: Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.
- Rests on an assumption: During mitosis, mitochondria are randomly segregated, and in heteroplasmic cells, the proportion of mutant mtDNA in the daughter cells can shift.
- Rests on an assumption: If the mutant load exceeds the pathogenic threshold for that tissue, clinical expression of the disease can occur.
- Rests on an assumption: Mutant mtDNA may be lost, particularly in fast-dividing tissues.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“they are not sufficient to counteract the oxidative damage sustained by the mitochondrial genome due to its proximity to the RC complexes in the IMM and the ROS they generate.Protective histones are also lacking.”
§ Review Mitochondrial DNA mutations and human disease > 3. Clinical features of human mtDNA disease
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although the threshold level can partly explain the disease phenotypes observed in patients, an exact correlation between clinical severity and the proportion of mtDNA mutation is lacking [62].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.1. Threshold effect
What the sources say
- Not checked yetcites [62] Wong, 2007, Diagnostic challenges of mitochondrial DNA disorders, Mitochondrion source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: In heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.
- Rests on an assumption: A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.
- Rests on an assumption: The threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.
- Rests on an assumption: Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.
None of the sources cited for this claim have been checked yet.
In the paper
“Clonal expansion refers to the preferential amplification of mtDNA mutations to a high level in post-mitotic tissues [64,65].”
§ Review Mitochondrial DNA mutations and human disease > 3.1.3. Clonal expansion
What the sources say
- Not checked yetcites [64] Larsson, 1990, Progressive increase of the mutated mitochondrial DNA fraction in Kearns–Sayre syndrome, Pediatr. Res. source
- Not checked yetcites [65] Weber, 1997, A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle, Am. J. Hum. Genet.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“CPEO is typically caused by sporadic large-scale single deletions or multiple mtDNA deletions [119,120], although mtDNA point mutations are detected in some patients (e.g., m.3243A N G [121], m.12316G N A [122]).”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.2. Chronic progressive external ophthalmoplegia (CPEO).
What the sources say
- Not checked yetcites [119] Moraes, 1989, Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns–Sayre syndrome, N. Engl. J. Med. source
- Not checked yetcites [120] Van Goethem, 2003, Progressive external ophthalmoplegia characterized by multiple deletions of mitochondrial DNA: unraveling the pathogenesis of human mitochondrial DNA instability and the initiation of a genetic classification, Neuromol. Med. source
- Not checked yetcites [121] Moraes, 1993, Atypical clinical presentations associated with the MELAS mutation at position 3243 of human mitochondrial DNA, Neuromuscul. Disord. source
- Not checked yetcites [122] Cardaioli, 2008, Chronic progressive external ophthalmoplegia: a new heteroplasmic tRNA(Leu(CUN)) mutation of mitochondrial DNA, J. Neurol. Sci. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Single mtDNA deletions occur sporadically early in development, and the identical deletion is present in all cells within affected tissues [87].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [87] Chen, 1995, Rearranged mitochondrial genomes are present in human oocytes, Am. J. Hum. Genet.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Leigh syndrome is due to severe failure of oxidative metabolism and can be due to a variety of different genetic defects affecting either the mitochondrial (e.g., m.8993T N C/G, m.10158T N C, m.10191T N C) or nuclear genome (e.g., SURF1 gene) [105].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.1. Mitochondrial diseases with onset in early infancy/childhood 3.3.1.1. Leigh syndrome.
What the sources say
- Not checked yetcites [105] Finsterer, 2008, Leigh and Leigh-like syndrome in children and adults, Pediatr. Neurol. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“They mainly occur between the origins of replication, O H and O L , and are typically flanked by short direct repeats [94,95].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [94] Bua, 2006, Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers, Am. J. Hum. Genet. source
- Not checked yetcites [95] Samuels, 2004, Two direct repeats cause most human mtDNA deletions, Trends Genet. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The majority of mtDNA rearrangement mutations are large-scale deletions, which vary in size from 1.3 to 8 kb and span several genes [86].”
§ Review Mitochondrial DNA mutations and human disease > 3.2.2. MtDNA rearrangements
What the sources say
- Not checked yetcites [86] Schon, 1989, A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA, Science source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whilst cybrids and yeast have helped to further our current understanding of mitochondrial genetics and the molecular mechanisms of disease, a mammalian in vivo model system is ultimately necessary for answering the many questions regarding mtDNA biology, mitochondrial disease pathogenesis and tissue specificity that still remain.”
§ Review Mitochondrial DNA mutations and human disease > 5.1.3. Mouse models
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition, these cell models have challenged our established criteria for pathogenicity with the identification of the first mt-tRNA suppressor mutation, m.12300G N A in MT-L2 [154], and the first functionally dominant mt-tRNA mutation, m.5545C N T in MT-TW [155].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.1. Transmitochondrial cybrids
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A global decrease in the activity of COX is usually suggestive of a nuclear mutation in an ancillary protein required for COX assembly such as SURF1 but can be associated with some homoplasmic mt-tRNA defects [77,78].”
§ Review Mitochondrial DNA mutations and human disease > 4.1. Histochemical and biochemical testing
What the sources say
- Not checked yetcites [77] McFarland, 2002, Multiple neonatal deaths due to a homoplasmic mitochondrial DNA mutation, Nat. Genet. source
- Not checked yetcites [78] Taylor, 2003, A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy, J. Am. Coll. Cardiol. source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The assessment of m.3243A N G mutation load in urinary sediments not only provides a correlate with the level in muscle but also has proven to be an accurate indicator of clinical outcome for these patients [138].”
§ Review Mitochondrial DNA mutations and human disease > 4.2. Molecular genetic testing
What the sources say
- Not checked yetcites [138] Whittaker, 2009, Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation, Neurology source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“By allowing selected mtDNA sequences to be expressed against fixed nuclear backgrounds, not only can cybrids be employed for establishing and/or confirming the genetic origin of a mitochondrial disorder, but they can also provide a controlled environment in which to study both the functional and physiological consequences of varying levels of heteroplasmy of specific mtDNA mutations as well as the”
§ Review Mitochondrial DNA mutations and human disease > 5.1.1. Transmitochondrial cybrids
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consequently, it is unlikely that a reduced respiration rate is solely responsible for this variability, but rather additional molecular mechanisms must also contribute to the development and clinical presentation of disease.”
§ Review Mitochondrial DNA mutations and human disease > 5. Functional characterisation of mtDNA mutations
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Clinical phenotypes of mitochondrial disorders are extremely heterogeneous.
- Rests on an assumption: Pathogenic mtDNA mutations invariably result in a general defect in mitochondrial respiration that leads to a reduced ability to produce cellular ATP.
In the paper
“Most importantly, this can be achieved in a highly controlled fashion as DNA delivered to mitochondria via biolistic transformation can only incorporate into the mitochondrial genome by homologous recombination [160].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.2. Yeast models
What the sources say
- Not checked yetcites [160] Bonnefoy, 2001, Genetic transformation of Saccharomyces cerevisiae mitochondria, Methods Cell Biol. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“However, the introduction over the past decade of an alternative model, the obligate aerobic yeast Yarrowia lipolytica, which possesses a vital proton-pumping NADH:ubiquinone oxidoreductase, has enabled important structural and functional analyses of mitochondrial complex I [168].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.2. Yeast models
What the sources say
- Not checked yetcites [168] Kerscher, 2004, Application of the yeast Yarrowia lipolytica as a model to analyse human pathogenic mutations in mitochondrial complex I (NADH:ubiquinone oxidoreductase), Biochim. Biophys. Acta source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Additional transmitochondrial mouse models, showing signs of mitochondrial dysfunction and capable of transmitting mtDNA mutations to subsequent generations, have since been established, including the 'Mito-mice' model that harbours high levels of a single heteroplasmic mtDNA deletion and shows a multitude of symptoms including myopathy, cardiomyopathy, renal failure, anaemia, deafness, lactic”
§ Review Mitochondrial DNA mutations and human disease > 5.1.3. Mouse models
What the sources say
- Not checked yetcites [172] Inoue, 2000, Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes, Nat. Genet. source
- Not checked yetcites [173] Nakada, 2004, Accumulation of pathogenic DeltamtDNA induced deafness but not diabetic phenotypes in mito-mice, Biochem. Biophys. Res. Commun. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Also, S. cerevisiae are inherently homoplasmic, thus precluding threshold studies, although it is possible to modulate the severity of yeast respiratory phenotypes by studying mt-tRNA mutations in different nuclear contexts [163,164].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.2. Yeast models
What the sources say
- Not checked yetcites [163] De Luca, 2006, Mutations in yeast mt tRNAs: specific and general suppression by nuclear encoded tRNA interactors, Gene source
- Not checked yetcites [164] Montanari, 2008, Yeast as a model of human mitochondrial tRNA base substitutions: investigation of the molecular basis of respiratory defects, Rna source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The progression of the disease seems to depend upon the responsible mutation with 71% of patients with the m.14484T N C mutation showing some recovery, compared to 25% with m.11778G N A [125].”
§ Review Mitochondrial DNA mutations and human disease > 3.3.2.4. Leber's hereditary optic neuropathy (LHON).
What the sources say
- Not checked yetcites [125] Riordan-Eva, 1995, The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation, Brain source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“For example, cybrids harbouring the homoplasmic MT-TV m.1624C N T mutation, which caused a profound metabolic defect in skeletal and cardiac muscle, with low complex I and IV activities, and resulted in multiple neonatal deaths [159], were found to lack the marked respiratory defect despite retaining a striking reduction in mt-tRNA Val steady-state levels [159].”
§ Review Mitochondrial DNA mutations and human disease > 5.1.1. Transmitochondrial cybrids
What the sources say
- Not checked yetcites [159] Rorbach, 2008, Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation, Nucleic Acids Res. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Increased ROS production has been described in neuronal NT2 cybrid cells containing m.3460G N A and m.11778G N A LHON mutations [187], in lymphocytes with m.8993T N C and m.8993T N G NARP mutations [188] and more recently in the chimeric m.3243A N G mice mentioned previously [175].”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
What the sources say
- Not checked yetcites [187] Wong, 2002, Differentiation-specific effects of LHON mutations introduced into neuronal NT2 cells, Hum. Mol. Genet. source
- Not checked yetcites [188] Baracca, 2007, Biochemical phenotypes associated with the mitochondrial ATP6 gene mutations at nt8993, Biochim. Biophys. Acta source
- Not checked yetcites [175] Li, 2008, Increased ROS generation and SOD activity in heteroplasmic tissues of transmitochondrial mice with A3243G mitochondrial DNA mutation, Genet. Mol. Res. source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Conversely, normal levels of ROS were measured in the POLG1 mutator mice, which eventually accumulate sufficient mtDNA mutations to cause severe OXPHOS deficiency [189].”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
What the sources say
- Not checked yetcites [189] Trifunovic, 2005, Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production, Proc. Natl. Acad. Sci. U. S. A. source
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Biochemical effects of mtDNA mutations have been well described in all experimental systems and are invariably characterised by lower cellular respiration, compromised RC complex activity, and reduced ATP synthesis.”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear? Based: unclearIt may state two separate claims as one.
In the paper
“and the mt-tRNA Tyr m.5874T N C and m.5877C N T transitions [204].”
§ Review Mitochondrial DNA mutations and human disease > 5.2.1. Molecular impacts of mt-tRNA mutations
What the sources say
- Not checked yetcites [204] Bonnefond, 2008, Decreased aminoacylation in pathology-related mutants of mitochondrial tRNATyr is associated with structural perturbations in tRNA architecture, RNA source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, no increase in programmed cell death was identified in this mouse model, contrary to a double TFAM knockout mouse model in which substantial apoptosis occurred at embryonic day 9.5 [179,190].”
§ Review Mitochondrial DNA mutations and human disease > 5.2. Molecular mechanisms of mitochondrial disease
What the sources say
- Not checked yetcites [179] Wang, 1999, Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression, Nat. Genet. source
- Not checked yetcites [190] Wang, 2001, Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression, Proc. Natl. Acad. Sci. U. S. A. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“However, although PNAs colocalised to mitochondria in intact cells, they were not able to cross the IMM.”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [234] Taylor, 1997, Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids, Nat. Genet. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Other shared transcriptional consequences of mitochondrial dysfunction include inhibition of both ubiquitin-mediated protein degradation and mitochondrial and nuclear ribosomal protein synthesis [214,215], as well as activation of the unfolded protein response [215,216].”
§ Review Mitochondrial DNA mutations and human disease > 5.2.2. Global effects of mtDNA mutations
What the sources say
- Not checked yetcites [214] Jahangir Tafrechi, 2005, Distinct nuclear gene expression profiles in cells with mtDNA depletion and homoplasmic A3243G mutation, Mutat. Res. source
- Not checked yetcites [215] Alemi, 2007, Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript, Free Radic. Biol. Med. source
- Not checked yetcites [216] Cortopassi, 2006, Mitochondrial disease activates transcripts of the unfolded protein response and cell cycle and inhibits vesicular secretion and oligodendrocyte-specific transcripts, Mitochondrion source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Moreover, the nature of the mtDNA mutations, in particular the m.9205delTA deletion, which eliminates the MT-ATP6 gene stop codon, placing MT-CO3 immediately in frame, and causes a marked decrease in RNA14 (MT-ATP8 and -6-encoding bicistronic transcript) steady-state levels [81]”
§ Review Mitochondrial DNA mutations and human disease > 5.2.2. Global effects of mtDNA mutations
What the sources say
- Not checked yetcites [81] Temperley, 2003, Investigation of a pathogenic mtDNA microdeletion reveals a translation-dependent deadenylation decay pathway in human mitochondria, Hum. Mol. Genet. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Muscle conditioning enhanced ATP levels, delayed disease onset, and increased life expectancy in these mice.”
§ Review Mitochondrial DNA mutations and human disease > 6.1. Exercise therapy
What the sources say
- Not checked yetcites [231] Wenz, 2009, Endurance exercise is protective for mice with mitochondrial myopathy, J. Appl. Physiol. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Well tolerated and safe, endurance training for up to 14 weeks has been found to improve OXPHOS function, although no concomitant shift in mutated mtDNA levels in muscle has been observed and cessation in training does cause a loss of the physiological adaptations [228][229][230].”
§ Review Mitochondrial DNA mutations and human disease > 6.1. Exercise therapy
What the sources say
- Not checked yetcites [228] Taivassalo, 2005, Exercise and training in mitochondrial myopathies, Med. Sci. Sports Exerc. source
- Not checked yetcites [229] Jeppesen, 2006, Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy, Brain source
- Not checked yetcites [230] Taivassalo, 2006, Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions, Brain source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Imported tRNA Lys molecules are correctly aminoacylated, able to participate in mitochondrial translation, and partially rescue mitochondrial functions [242].”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [242] Kolesnikova, 2004, Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERRF syndrome in cultured human cells, Hum. Mol. Genet. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The most recent mammalian mitochondrial compendium (MitoCarta) consists of 1098 identified proteins [209].”
§ Review Mitochondrial DNA mutations and human disease > 5.2.2. Global effects of mtDNA mutations
What the sources say
- Not checked yetcites [209] Pagliarini, 2008, A mitochondrial protein compendium elucidates complex I disease biology, Cell source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, two recent studies have demonstrated an increase in mutant mt-tRNA Val [159] and mt-tRNA Leu(UUR) [166] steady-state levels following overexpression of the valyl and leucyl synthetases, respectively.”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [159] Rorbach, 2008, Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation, Nucleic Acids Res. source
- Not checked yetcites [166] Park, 2008, Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene, Rna source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Twelve-week resistance training studies in patients with single, large-scale mtDNA deletions have been demonstrated to increase satellite cell number with concomitant improvements in muscular strength and oxidative capacity evidenced by a decrease in the proportion of COX-negative fibres [233].”
§ Review Mitochondrial DNA mutations and human disease > 6.1. Exercise therapy
What the sources say
- Not checked yetcites [233] Murphy, 2008, Resistance training in patients with single, large-scale deletions of mitochondrial DNA, Brain source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Indeed, AOX was well tolerated and transfectants displayed remarkable levels of cyanide resistance to mitochondrial metabolite oxidation.”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [247] Hakkaart, 2006, Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration, EMBO Rep. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“However, studies in heteroplasmic mice have demonstrated almost identical levels of heteroplasmy between the ooplasm and polar body of the mature oocyte and also between individual blastomeres [250].”
§ Review Mitochondrial DNA mutations and human disease > 6.3. Prevention of mtDNA disease transmission
What the sources say
- Not checked yetcites [250] Dean, 2003, Prospect of preimplantation genetic diagnosis for heritable mitochondrial DNA diseases, Mol. Hum. Reprod. source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“An alternative approach involving pronuclear transfer, the transfer of the pronuclei from a fertilised zygote of a mother with mtDNA disease to an enucleated zygote from a healthy donor female, is presently being investigated in abnormally fertilised human embryos (Turnbull et al., unpublished data).”
§ Review Mitochondrial DNA mutations and human disease > 6.3. Prevention of mtDNA disease transmission
What the sources say
- Not checked yetcites Turnbull et al., unpublished data
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Recently, spindle-chromosome complex transfer from a mature primate oocyte to an enucleated primate egg successfully produced healthy offspring, in which, importantly, spindle donor mtDNA was not detected [252].”
§ Review Mitochondrial DNA mutations and human disease > 6.3. Prevention of mtDNA disease transmission
What the sources say
- Not checked yetcites [252] Tachibana, 2009, Mitochondrial gene replacement in primate offspring and embryonic stem cells, Nature source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Furthermore, an encouraging strategy for the potential rescue of mitochondrial COX defects may soon be possible following the successful transfection and IMM targeting in human cultured cells of the sea squirt Ciona intestinalis cyanide-insensitive alternative oxidase (AOX) [247].”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [247] Hakkaart, 2006, Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration, EMBO Rep. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Similarly, xenotopic expression of the green alga Chlamydomonas reinhardtii ATPase 6 (CrATP6) in human cybrid cells harbouring the m.8993T N G mutation resulted in moderately improved ATP production whilst cellular viability was fully recovered [246].”
§ Review Mitochondrial DNA mutations and human disease > 6.2. Gene therapy
What the sources say
- Not checked yetcites [246] Ojaimi, 2002, An algal nucleus-encoded subunit of mitochondrial ATP synthase rescues a defect in the analogous human mitochondrial-encoded subunit, Mol. Biol. Cell source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
In heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.
“In the presence of heteroplasmy, the ratio of wild-type to mutant mtDNA determines the onset of clinical symptoms.”
The paper relies on this without support.
A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.
“A minimum critical proportion of mutated mtDNAs is necessary before biochemical defects and tissue dysfunction become apparent.”
The paper relies on this without support.
The threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.
“This threshold level varies for each mutation and differs amongst tissues, being lower in tissues highly dependent on OXPHOS metabolism than in tissues that can rely on anaerobic glycolysis.”
The paper relies on this without support.
Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.
“Typically, the threshold value is in the range of 60%-90% mutant to wild-type mtDNA.”
The paper relies on this without support.
During mitosis, mitochondria are randomly segregated, and in heteroplasmic cells, the proportion of mutant mtDNA in the daughter cells can shift.
“During mitosis, mitochondria are randomly segregated, and in heteroplasmic cells, the proportion of mutant mtDNA in the daughter cells can thus shift.”
The paper relies on this without support.
If the mutant load exceeds the pathogenic threshold for that tissue, clinical expression of the disease can occur.
“Should the mutant load exceed the pathogenic threshold for that tissue, clinical expression of the disease can occur.”
The paper relies on this without support.
Mutant mtDNA may be lost, particularly in fast-dividing tissues.
“Conversely, mutant mtDNA may be lost, particularly in fast-dividing tissues.”
The paper relies on this without support.
MtDNA point mutations are usually maternally inherited.
“MtDNA point mutations are usually maternally inherited.”
The paper relies on this without support.
More than half of disease-related point mutations reported are located within mt-tRNA genes.
“However, more than half of disease-related point mutations reported are located within mt-tRNA genes.”
The paper relies on this without support.
Point mutations in mitochondrial protein-coding genes specifically affect the function of the RC complex to which the corresponding protein belongs, whereas mt-tRNA mutations may impair overall mitochondrial translation by reducing the availability of functional mt-tRNAs.
“Phenotypically, point mutations in mitochondrial protein-coding genes specifically affect the function of the RC complex to which the corresponding protein belongs, whereas mt-tRNA mutations may impair overall mitochondrial translation by reducing the availability of functional mt-tRNAs.”
The paper relies on this without support.
Point mutations are mostly heteroplasmic, displaying considerable clinical heterogeneity, and are considered highly recessive.
“Point mutations are mostly heteroplasmic, displaying considerable clinical heterogeneity, and are considered highly recessive.”
The paper relies on this without support.
LHON is usually due to a homoplasmic mtDNA mutation and all maternal offspring will inherit the mutation; however, whilst 50% of males will be affected, only 10% of females will develop visual loss.
“LHON is usually due to a homoplasmic mtDNA mutation and all maternal offspring will inherit the mutation; however, whilst 50% of males will be affected, only 10% of females will develop visual loss.”
The paper relies on this without support.
The clinical syndromes associated with mtDNA mutations are extremely variable and patients can present at any stage in life.
“The clinical syndromes associated with mtDNA mutations are extremely variable and patients can present at any stage in life.”
The paper relies on this without support.
On the whole, the age of onset reflects the level of mutation and the severity of the biochemical defect, but other factors (presumably nuclear genetic or environmental) also affect the expression of disease.
“On the whole, the age of onset reflects the level of mutation and the severity of the biochemical defect, but other factors (presumably nuclear genetic or environmental) also effect the expression of disease.”
The paper relies on this without support.
Many, but not all, patients with mtDNA disease show histological and histochemical changes in affected tissue, indicative of RC dysfunction.
“Many, but not all, patients with mtDNA disease show histological and histochemical changes in affected tissue, indicative of RC dysfunction.”
The paper relies on this without support.
Some mutations—mtDNA rearrangements and certain mtDNA point mutations—are only present in clinically affected tissues, necessitating the work-up on postmitotic (muscle) DNA samples.
“Some mutations-mtDNA rearrangements and certain mtDNA point mutations-are only present in clinically affected tissues, necessitating the work-up on postmitotic (muscle) DNA samples.”
The paper relies on this without support.
Due to its small size, screening the entire mitochondrial genome can be undertaken relatively easily to identify rare or novel mtDNA mutations in patients with suspected mtDNA disease.
“Due to its small size, screening the entire mitochondrial genome can be undertaken relatively easily to identify rare or novel mtDNA mutations in patients with suspected mtDNA disease.”
The paper relies on this without support.
Clinical phenotypes of mitochondrial disorders are extremely heterogeneous.
“The clinical phenotypes of mitochondrial disorders are however extremely heterogeneous.”
The paper relies on this without support.
Engineering mtDNA is problematic due to its polyploidy, inaccessibility within a double-membraned organelle, and apparent lack of, or minimal, recombination, which have prevented the successful transfection of autonomously replicating foreign DNA plasmids or modified mtDNA into mitochondria to date.
“Firstly, engineering mtDNA is problematic due to its polyploidy, inaccessibility within a double-membraned organelle, and apparent lack of, or minimal, recombination, which have prevented the successful transfection of autonomously replicating foreign DNA plasmids or modified mtDNA into mitochondria to date.”
The paper relies on this without support.
Most cybrid models are generated using aneuploid tumour cells.
“Most cybrid models are generated using aneuploid tumour cells.”
The authors state this as an assumption.
Aneuploidy can affect the stoichiometry of nuclear- and mitochondrial-encoded RC subunits, thus interfering with genotype-phenotype relationships.
“however, it is reasonable to assume that it can affect the stoichiometry of nuclear-and mitochondrial-encoded RC subunits, thus interfering with genotype-phenotype relationships.”
The paper relies on this without support.
Tumour cells are largely glycolysis-dependent, relying little on OXPHOS for generating the majority of their energy requirements.
“On a similar note, tumour cells are largely glycolysis-dependent, relying little on OXPHOS for generating the majority of their energy requirements.”
The paper relies on this without support.
mtDNA disorders typically occur in highly aerobic cells.
“In contrast, mtDNA disorders typically occur in highly aerobic cells.”
The paper relies on this without support.
S. cerevisiae is currently the only known organism in which mitochondrial genetic transformation is possible.
“Saccharomyces cerevisiae is currently the only known organism in which mitochondrial genetic transformation is possible.”
The paper relies on this without support.
S. cerevisiae can survive in the complete absence of functional mtDNA.
“Furthermore, in view of the ability of S. cerevisiae to survive in the complete absence of functional mtDNA, the study of very severe mitochondrial defects is possible.”
The paper relies on this without support.
Not all human mt-tRNAs share strong homology with yeast mt-tRNAs.
“Not all human mt-tRNAs share strong homology with yeast mt-tRNAs.”
The paper relies on this without support.
Fermentative yeast such as S. cerevisiae lack complex I.
“Finally, fermentative yeast such as S. cerevisiae lack complex I.”
The paper relies on this without support.
It is not possible to directly manipulate the mouse mitochondrial genome.
“As it is not possible to directly manipulate their mitochondrial genome, researchers have been forced to adopt more ingenious and indirect ways of engineering mouse mtDNA.”
The paper relies on this without support.
No effective treatment options are currently available for patients with mitochondrial dysfunction, except in rare cases where surgery or transplant may be indicated.
“Despite considerable advances over the last decade in our understanding of mitochondrial genetics and function and the pathogenesis of mtDNA diseases, no effective treatment options are currently available for patients with mitochondrial dysfunction, except in rare cases where surgery or transplant may be indicated.”
The paper relies on this without support.
Satellite cells proliferate in response to damage caused by concentric or eccentric muscular contractions.
“Undifferentiated myogenic cells, satellite cells, are known to proliferate in response to damage caused by concentric (shortening) or eccentric (lengthening) muscular contractions.”
The paper relies on this without support.
Pathogenic mtDNA mutations invariably result in a general defect in mitochondrial respiration that leads to a reduced ability to produce cellular ATP.
“Pathogenic mtDNA mutations invariably result in a general defect in mitochondrial respiration that leads to a reduced ability to produce cellular ATP.”
The paper relies on this without support.
No effective therapies or cures are presently available for patients with mtDNA disease.
“Disappointingly, no effective therapies or cures are presently available for patients with mtDNA disease.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, estimates have increased the mutation rate from 10- to 17-fold higher in mtDNA than nuclear genomic (nDNA) (Tuppen et al., 2010).”
From Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases (2017) · cites this paper as Tuppen et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
LHON mutation is given in opposite directions
MinorThe LHON section identifies the mutation at position 11778 as G to A, but later in the same paragraph calls it A to G.
“There are three primary LHON mtDNA mutations (m.11778G N A, m.3460G N A, and m.14484T N C)”
“Whilst the majority of patients with m.11778A N G who have symptoms develop LHON”
Figure 1's list of 13 polypeptides omits ND5 and ND6
MinorThe figure caption presents its list as the 13 mtDNA-encoded respiratory-chain polypeptides, but the listed names account for only 11. Elsewhere the paper identifies MT-ND6 as an mtDNA gene, which is absent from that list; it also discusses MT-ND5.
“13 essential RC polypeptides: ND1-ND4 and ND4L, subunits of complex I (green), CYTB, a subunit of complex III (purple), COI-COIII, catalytic subunits of complex IV (yellow), and ATP6 and ATP8, subunits of complex V (blue).”
“Two heteroplasmic point mutations introduced in MT-ND6 (m.13885insC) and MT-CO1 (m.6589T N C) resulted in myopathy and cardiomyopathy [174]”
Citations
Cites
1 retracted
Endurance exercise is protective for mice with mitochondrial myopathy
Wenz, T., Diaz, F., Hernandez, D., & Moraes, C. T. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.91571.2008 · Cited by 78 · cited 1×
“Recently, the bene fi ts of daily aerobic exercise have been further demonstrated in conditional COX10 knockoutmice,whichtypicallydevelopseveremyopathy at ∼ 2.5 – 3 months [231].”
BackgroundInfluentialRetractedSequence and organization of the human mitochondrial genome
Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H. L., Coulson, A. R., Drouin, J., Eperon, I. C., Nierlich, D. P., Roe, B. A., Sanger, F., et al. (1981) · Nature · doi:10.1038/290457a0 · Cited by 9,740
Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA
Andrews, R. M., Kubacka, I., Chinnery, P. F., Lightowlers, R. N., Turnbull, D. M., & Howell, N. (1999) · Nature Genetics · doi:10.1038/13779 · Cited by 3,337 · cited 1×
“heavy (H) strands), circular genome, the complete sequence of which was fully elucidated in 1981 [11] and further revised in 1999 [12].”
BackgroundSelf-citationPremature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Alternative and more successful approaches to developing mouse models of mitochondrial disease involve manipulating the nuclear genes that regulate mtDNA maintenance and replication, such as TFAM [176 – 182], POLG ( ‘ Mutator ’ model) [183], and PEO1 (Twinkle; ‘ Deletor ’ model) [184].”
BackgroundtRNA punctuation model of RNA processing in human mitochondria
Ojala, D., Montoya, J., & Attardi, G. M. (1981) · Nature · doi:10.1038/290470a0 · Cited by 2,561 · cited 2×
“Mitochondrial translation is characterised by a number of distinct features including RNA-poor mitoribosomes [48], bicistronic transcripts [49], partial stop codons in some of the transcripts that are completed by polyadenylation [31,50], and deviation from the standard genetic code.”
BackgroundMitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440 · cited 1×
“The fi rst pathogenic mtDNA mutations were identi fi ed in 1988 [54,55].”
BackgroundGoto, Y.-I., Nonaka, I., & Horai, S. (1990) · Nature · doi:10.1038/348651a0 · Cited by 2,070 · cited 1×
“Over 80% of patients with MELAS have the m.3243A N G mutation in the MT-TL1 gene [109,110].”
BackgroundA Mitochondrial Protein Compendium Elucidates Complex I Disease Biology
Pagliarini, D. J., Calvo, S. E., Chang, B., Sheth, S. A., Vafai, S. B., Ong, S.-E., Walford, G. A., Sugiana, C., Boneh, A., Chen, W. K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.016 · Cited by 1,994 · cited 3×
“understanding of the role of mitochondria in health and disease [209,225,226].”
BackgroundMethodInfluentialMitochondrial DNA mutations in human disease
Taylor, R. W., & Turnbull, D. M. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1606 · Cited by 1,922
Self-citationDeletions of muscle mitochondrial DNA in patients with mitochondrial myopathies
Holt, I. J., Harding, A. E., & MORGAN-HUGHES, J. A. (1988) · Nature · doi:10.1038/331717a0 · Cited by 1,860 · cited 2×
“The fi rst pathogenic mtDNA mutations were identi fi ed in 1988 [54,55].”
BackgroundMethod
Flagged first, then by citations
11 of the 272 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Chen, 1995, Rearranged mitochondrial genomes are present in human oocytes, Am. J. Hum. Genet., 57, 239
- Oefner, 1995, Comparative DNA sequencing by high-performance liquid chromatography, Am. J. Hum. Genet., 57, A266
Cited by
Sorted by citations
Items 301–400 of 681
Induced pluripotent stem cells: ex vivo models for human diseases due to mitochondrial DNA mutations
Chen, C., & Guan, M. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00967-7 · Cited by 18
“…or protection of histones makes mtDNA more vulnerable to reactive oxygen species (ROS), generated in mitochondrial electron transport chain [1, 13]. mtDNA mutations also arise from defects in the biogenesis and mtDNA maintaince, reflecting the contribution of nuclear-encoded genes such as…”
BackgroundInfluentialAguilar, K., Jakubek, P., Antonio Zorzano, A., & Wieckowski, M. R. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14217 · Cited by 19
“…of the mtDNA copies (heteroplasmy), the emergence of the biochemical defect and clinical manifestation of the disease strictly depends on the threshold level (number of mutated mtDNA copies), which is a basis for a wide variety of diseases with heterogenic phenotypes (for review see Ref [1]).”
BackgroundYoung, T., Blakely, E. L., Swalwell, H., Carter, J., Kartsounis, L. D., O’Donovan, D. G., Turnbull, D. M., Taylor, R. W., & de Silva, R. N. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.283 · Cited by 17
“M ITOCHONDRIAL DNA (mtDNA)mutationsare associated with markedly heterogeneous phenotypic and genetic profiles, are not uncommon, and are probably underdiagnosed.(1) Mitochondria may play a critical role in the etiopathogenesis of Parkinson disease, and mutations in several nuclear-encoded genes linked with inherited P…”
BackgroundSelf-citationPaepe, B. D., & Coster, R. V. (2017) · Nutrients · doi:10.3390/nu9091017 · Cited by 18
The Role of Mitochondrial Genes in Neurodegenerative Disorders
Kumar, R., Harilal, S., Parambi, D. G. T., Kanthlal, S. K., Rahman, M. A., Alexiou, A. T., Batiha, G. E., & Mathew, B. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210908163839 · Cited by 16
“Mutagenesis can produce mutations that can be neutral or pathogenic and can produce primary mitochondrial disease, depending on the kind of mutation [28, 29].”
Li, Z., Li, S., Lv, H., Shen, J., He, X., & Peng, B. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.120766 · Cited by 18
Wragg, D., Techer, M. A., Canale‐Tabet, K., Basso, B., Bidanel, J. P., Labarthe, E., Bouchez, O., Conte, Y. L., Clémencet, J., Delatte, H., et al. (2017) · Genome Biology and Evolution · doi:10.1093/gbe/evx247 · Cited by 18
“We also found SNPs and indels in tRNA genes differentiating subspecies, and some of these may have an impact on general metabolism, as has been demonstrated for mutations in human tRNA genes that have been associated with diseases (Tuppen et al. 2010; Suzuki et al. 2011).”
THz spectra and corresponding vibrational modes of DNA base pair cocrystals and polynucleotides
Wang, F., Zhao, D., Dong, H., Jiang, L., Huang, L., Liu, Y., & Li, S. (2018) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2018.04.024 · Cited by 16
Molecular differences in mitochondrial DNA genomes of dogs with malignant mammary tumours
Kowal, K., Tkaczyk‐Wlizło, A., Pierzchała, M., Gawor, J., & Ślaska, B. (2021) · Veterinary and Comparative Oncology · doi:10.1111/vco.12772 · Cited by 17
Fish Models for Exploring Mitochondrial Dysfunction Affecting Neurodegenerative Disorders
Otsuka, T., & Matsui, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087079 · Cited by 17
Mitochondrial base editing: from principle, optimization to application
Tang, J., & Du, K. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01351-8 · Cited by 18
A matter of life, death and diseases: mitochondria from a proteomic perspective
Warda, M., Kim, H. K., Kim, N., Ko, K. S., Rhee, B. D., & Han, J. (2013) · Expert Review of Proteomics · doi:10.1586/epr.12.69 · Cited by 16
Dobson, P. F., Rocha, M. C., Grady, J. P., Chrysostomou, A., Hipps, D., Watson, S., Greaves, L. C., Deehan, D. J., & Turnbull, D. M. (2016) · Scientific Reports · doi:10.1038/srep31907 · Cited by 17
Self-citationAn Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma
Sarnecka, A. K., Zagozda, M., & Durlik, M. (2016) · Journal of Cancer · doi:10.7150/jca.15323 · Cited by 16
“Mitochondrial genome is able to independent (to nuclear DNA) replication [59], however some connections with cell cycle are suggested [61].”
BackgroundSato, G. E., & Kuroda, K. (2023) · Microorganisms · doi:10.3390/microorganisms11041040 · Cited by 16
“significant attention as targets for genome editing due to their potential for treating human genetic diseases arising from mutations in mitochondrial DNA (mtDNA) [15].”
BackgroundThe emerging molecular mechanisms for mitochondrial dysfunctions in FXTAS
Gohel, D., Charlet‐Berguerand, N., Tassone, F., & Singh, R. K. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165918 · Cited by 17
Elrahman, M. M. A., Makawy, A. I. E., Hassanane, M. S., et al. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-020-00111-0 · Cited by 15
“Therefore, the range of mtDNA mutation is considerably high (10–17-fold higher) compared to nuclear DNA [10, 12].”
BackgroundPhotoreceptor Manifestations of Primary Mitochondrial Optic Nerve Disorders
Chang, Y., Kang, E. Y., Liu, P., Levi, S. R., Wang, H.-H., Tseng, Y.-J., Seo, G. H., Lee, H., Yeh, L., Chen, K., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.5.5 · Cited by 14
“4,5 In human eyes, the retina and neurons are among the most metabolically active tissue.”
Fluorescent in situ hybridization of mitochondrial DNA and RNA.
Alán, L., Zelenka, J., Ježek, J., et al. (2010) · Acta Biochimica Polonica · doi:10.18388/abp.2010_2425 · Cited by 15
Mkaouar‐Rebai, E., Chamkha, I., Kammoun, T., et al. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.04.003 · Cited by 15
Broz, A. K., Keene-Snickers, A. H., Gyorfy, M. F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.28.486093 · Cited by 15
Mic60 is essential to maintain mitochondrial integrity and to prevent encephalomyopathy
Dong, T., Zhang, Z., Sun, L., Zhang, W., Zhu, Z., Lin, L., Yang, L., Lv, A., Liu, C., Li, Q., et al. (2023) · Brain Pathology · doi:10.1111/bpa.13157 · Cited by 13
The clinical spectrum of MELAS and associated disorders across ages: a retrospective cohort study
Cox, B. C., Pearson, J. Y., Mandrekar, J. N., & Gavrilova, R. H. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1298569 · Cited by 14
Non-toxic fluorescent phosphonium probes to detect mitochondrial potential
Šarić, A., Crnolatac, I., Bouillaud, F., et al. (2017) · Methods and Applications in Fluorescence · doi:10.1088/2050-6120/aa5e64 · Cited by 14
Jaweesh, M. S., Hammadeh, M. E., Dahadhah, F. W., et al. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07200-y · Cited by 14
“Expectedly, alterations in the mitochondrial DNA can cause diseases through various mechanisms such as interference with the oxidative phosphorylation (OXPHOS) function which is the most significant interruption [15].”
BackgroundKasashima, K., & Endo, H. (2015) · Genes to Cells · doi:10.1111/gtc.12306 · Cited by 14
“Mutations or deletions in mtDNA have been implicated in the development of several neuromuscular diseases (Tuppen et al. 2010).”
BackgroundZohour, M. M., Tabatabaiefar, M. A., Dehkordi, F. A., et al. (2011) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0176 · Cited by 14
“Mutations in three mitochondrial genes, MT-RNR1 , MT-TL1, and MTTS1 , encoding the 12S ribosomal RNA, tRNA Leu(UUR) , and tRNA Ser(UCN) , respectively, mainly cause HI (Prezant et al. , 1993; Reid et al. , 1994, 1997; Li et al. , 2004; Tuppen et al. , 2010).”
Bale, S. S., Kwon, S., Shah, D. A., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22897 · Cited by 14
“Owing to their role in a variety of cellular functions, such as energy production and control of apoptosis, mitochondria have been one of the most studied cell organelles for aberrant cell behavior (Boddapati et al., 2008; Fulda and Kroemer, 2009; Taylor and Turnbull, 2005; Tuppen et al., 2010; Zeviani and Di Donato,…”
BackgroundKapur, R. P. (2014) · Springer eBooks · doi:10.1007/978-3-642-54053-0_7 · Cited by 14
mity : A highly sensitive mitochondrial variant analysis pipeline for whole genome sequencing dataPreprint
Puttick, C., Kumar, K. R., Davis, R. L., Pinese, M., Thomas, D. M., Dinger, M. E., Sue, C. M., & Cowley, M. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/852210 · Cited by 12
“The human MT genome is a 16,569bp circular chromosome encoding rRNA, tRNA and protein coding genes [3] and has a mutation rate 19× higher than the nuclear genome [6].”
BackgroundEngineered S. cerevisiae construction for high-gravity ethanol production and targeted metabolomics
Yang, P., Feng, J., & Chen, J. (2025) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-025-13446-w · Cited by 13
“The potential editing targets also existed in mitochondria and chloroplasts (Tuppen et al. 2010).”
Vostatek, R., Hohensinner, P. J., Nopp, S., Haider, P., Englisch, C., Pointner, J., Pabinger, I., & Ay, C. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.01.031 · Cited by 14
Mitochondrial perturbation in immune cells enhances cell-mediated innate immunity in Drosophila
Salminen, T. S., Vesala, L., Basikhina, Y., Kutzer, M. A. M., Tuomela, T., Lucas, R., Monteith, K., Prakash, A., Tietz, T., & Vale, P. F. (2024) · BMC Biology · doi:10.1186/s12915-024-01858-5 · Cited by 15
Kumar, K., Venturas, M., Needleman, D. J., Racowsky, C., & Wells, D. (2021) · Human Reproduction · doi:10.1093/humrep/deab231 · Cited by 13
“The presence of mtDNA variants and mutations has also been linked to several human diseases, including cancers, as well as neurological and cardiological disorders (Taylor and Turnbull, 2005; Tuppen et al., 2010; Alvarez-Mora et al., 2020; Jahani et al., 2020).”
BackgroundObeng, E., Ding, F., He, X., & Shen, J. (2021) · Dyes and Pigments · doi:10.1016/j.dyepig.2021.109964 · Cited by 13
Argente‐Escrig, H., Vilchez, J. J., Frasquet, M., Muelas, N., Azorı́n, I., Vílchez, R., Millet, E., Castellano, I. P., Vila, M. T., Vazquez-Costa, J. F., et al. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12817 · Cited by 13
Shukla, P., Mukherjee, S., Patil, A. D., & Joshi, B. N. (2022) · Gene · doi:10.1016/j.gene.2022.147126 · Cited by 13
Bacalhau, M., Simões, M., Rocha, M. C., Hardy, S. A., Vincent, A. E., Durães, J., Macário, C., Santos, M. J., Rebelo, O., Lopes, C., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.11.006 · Cited by 13
“The pathogenic variants in mt-tRNA genes may impair transcription termination and tRNA maturation, reduce the aminoacylation, abolish post-transcriptional modification of tRNA, decrease the binding to translation factors or the mitoribosome, alter the structure, perturb the stability, and disturb codon reading, ultima…”
BackgroundSelf-citationGonzalez, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.636294 · Cited by 19
Differential mitochondrial genome in patients with Rheumatoid Arthritis
Jaiswal, K. S., Khanna, S., Ghosh, A., Padhan, P., Raghav, S. K., & Gupta, B. (2021) · Autoimmunity · doi:10.1080/08916934.2020.1846182 · Cited by 12
Gowen, A. M., Yi, J., Stauch, K. L., Miles, M. W., Srinivasan, S., Odegaard, K. E., Pendyala, G., & Yelamanchili, S. V. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100669 · Cited by 12
Mitochondrial DNA variants in the pathogenesis and metabolic alterations of diabetes mellitus
S, P. K. K., Jyothi, M. N., & Prashant, A. (2024) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2024.101183 · Cited by 17
Multifunctional Enveloped Nanodevices (MENDs)
Sato, Y., Nakamura, T., Yamada, Y., Akita, H., & Harashima, H. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00006-7 · Cited by 13
Amai, T., Tsuji, T., Ueda, M., & Kuroda, K. (2020) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaa119 · Cited by 12
Yang, F., Yang, D., Wang, L., et al. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132820 · Cited by 12
Ramil‐Gómez, O., López-Pardo, M., Fernández-Rodríguez, J. A., et al. (2022) · Antioxidants · doi:10.3390/antiox11112184 · Cited by 12
“Another key event is the high mutation rate associated with mtDNA that is mainly due to the action of ROS production [8,9].”
BackgroundLehmann, D., Schubert, K., Joshi, P. R., Baty, K., Blakely, E. L., Zierz, S., Taylor, R. W., & Deschauer, M. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.09.008 · Cited by 12
“This threshold level varies for each mutation and tissue and is dependent on the OXPHOS metabolism of the tissue [6].”
BackgroundSelf-citationPrivate Mitochondrial DNA Variants in Danish Patients with Hypertrophic Cardiomyopathy
Hagen, C. M., Aidt, F., Havndrup, O., Hedley, P. L., Jensen, M. K., Kanters, J. K., Pham, T. T., Bundgaard, H., & Christiansen, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124540 · Cited by 12
Influence of Mtdna Genetic Variation on Antibiotic Therapy
Pacheu‐Grau, D., Gómez-Durán, A., Montoya, J., et al. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.115 · Cited by 12
Functional Outcome of Children With Mitochondrial Diseases
Rogač, M., Meznarič, M., Zeviani, M., et al. (2011) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2010.12.004 · Cited by 12
“In the last 3 decades, numerous studies have been performed on the genetic and biochemical background, with many new pathogenic mutations and defective proteins being discovered [4-7].”
BackgroundVariations in mitochondrial tRNA Thr gene may not be associated with coronary heart disease
Pei, H., Peng, Q., Lan, C., & Liu, B. C. (2014) · Mitochondrial DNA Part A · doi:10.3109/19401736.2014.905862 · Cited by 12
Gene therapy for the mitochondrial genome: Purging mutations, pacifying ailments
Siva, A., Mahalakshmi, R., Bhakta-Guha, D., & Guha, G. (2018) · Mitochondrion · doi:10.1016/j.mito.2018.06.002 · Cited by 12
Advancement in the diagnosis of mitochondrial diseases
Sulaiman, S. A., Rani, Z. M., Radin, F. Z. M., & Murad, N. A. A. (2020) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2020.27 · Cited by 13
“mtDNA diseases have five unique characteristics, based on the mtDNA disease pedigree([1,7]).”
BackgroundInfluentialMitochondrial myopathy associated with a novel 5522G>A mutation in the mitochondrial tRNATrp gene
Barić, I., Fumić, K., Ramadža, D. P., Sperl, W., Zimmermann, F., Muačević‐Katanec, D., Mitrović, Z., Pažanin, L., Šojat, L. C., Kekez, T., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.272 · Cited by 12
Silkjær, T., Nyvold, C. G., Juhl‐Christensen, C., Hokland, P., & Nørgaard, J. M. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12166 · Cited by 11
“This is often the case in mitochondrial disorders (51).”
BackgroundRommelaere, G., Michel, S., Malaisse, J., et al. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.10.009 · Cited by 11
Energy metabolism and sources of oxidative stress in wooden breast - a review
Hubert, S. M., & Athrey, G. (2020) · F1000Research · doi:10.12688/f1000research.23296.1 · Cited by 11
“However, the mitochondrion is the only organelle in the cell with a genome (Koch, 2016; Latorre-Pellicer et al., 2016; Tuppen et al., 2010; Wallace & Chalkia, 2013; Yarham et al., 2010).”
BackgroundInfluentialMitochondrial genome variant m.3250T>C as a possible risk factor for mitochondrial cardiomyopathy
Campbell, T., Lou, X., Slone, J. D., et al. (2020) · Human Mutation · doi:10.1002/humu.24143 · Cited by 11
“2021;42:177–188. wileyonlinelibrary.com/journal/humu © 2020 Wiley Periodicals LLC | 177 Teresa Campbell and Xiaoting Lou are co‐first authors. impacting disease interpretation (Tuppen et al., 2010).”
BackgroundÖzkan, Y., Kandemır, H., Sapmaz, Ş. Y., Taneli, F., Özdemir, H., & Özkan, Ö. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.084 · Cited by 11
Namslauer, I., Lee, H. J., Gennis, R. B., & Brzezinski, P. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.01.027 · Cited by 11
“Typically, mtDNA mutations are recognized as causes of primary, mitochondrial diseases such as mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged red fibers (MERRF) and Kearns–Sayre syndrome (KSS) due to the mutations accumulating to high levels in muscle…”
Cortes‐Figueiredo, F., Carvalho, F. S., Fonseca, A. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112031 · Cited by 10
“Additionally, mtDNA shows a higher mutation rate due to the absence of protective histones, exposure to reactive oxygen and nitrogen species, and more rudimentary repair systems [1,2].”
BackgroundFelhi, R., Mkaouar‐Rebai, E., Sfaihi, L., Alila‐Fersi, O., Tabebi, M., Rhouma, B. B., Ammar, M., Keskes, L., Hachicha, M., & Fakhfakh, F. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.050 · Cited by 10
Li, D., Du, X., Guo, X., Zhan, L., Li, X., Yin, C., Cheng, C., Li, M., Li, B., Yang, H., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0638-6 · Cited by 11
“Due to the lack of protective histones and efficient DNA repair system, the mutation frequency of mtDNA is about 10 times higher than that of nuclear DNA [2].”
BackgroundKang, Y., Hyun, J., & Hwang, C. (2022) · Veterinary Dermatology · doi:10.1111/vde.13114 · Cited by 11
Mogilicherla, K., CHATTERJEE, R. N., Reddy, M. R., Dange, M., & Bhattacharya, T. K. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1083976 · Cited by 10
“mtDNA mutations contribute to enclosing both tissuespecific and multiple-system disorders in human diseases (Taylor and Turnbull, 2005; Tuppen et al., 2010).”
BackgroundMitochondrial genome variability: the effect on cellular functional activity
Volobueva, A. S., Melnichenko, A. А., Grechko, A. V., & Orekhov, A. N. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s153895 · Cited by 12
“The established values of this threshold are about 60%–90%, being lower in tissues more relying on oxidative phosphorylation.(26) The threshold also varies according to the type of mutations, being approximately 50%–60% and 70%–90% for mtDNA deletion and point mutations, respectively.”
G-quadruplex formation by single-base mutation or deletion of mitochondrial DNA sequences
Chu, I.-T., Wu, C.-C., & Chang, T. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.11.009 · Cited by 10
Harino, T., Tanaka, K., Motooka, D., Masuike, Y., Takahashi, T., Yamashita, K., Saito, T., Yamamoto, K., Makino, T., Kurokawa, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80226-3 · Cited by 10
Investigation of Mitochondrial Related Variants in a Cerebral Small Vessel Disease Cohort
Dunn, P. J., Harvey, N. R., Maksemous, N., Smith, R. A., Sutherland, H. G. E., Haupt, L. M., & Griffiths, L. R. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02914-3 · Cited by 10
Bennani‐Baïti, B., & Bennani-Baı̈ti, I. M. (2011) · Gene · doi:10.1016/j.gene.2011.09.035 · Cited by 9
“Mutations inMT-ND1/ND1 underlie several disorders including Leber hereditary optic neuropathy (LHON), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome (MELAS), several cancers, and may also be associated with Alzheimer disease mitochondrial (AD-MT) and with non-insulin-dependent d…”
BackgroundKim, M., Cho, S., Lee, J. H., Seo, H. J., & Lee, S. D. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e337 · Cited by 10
The role of mitochondria in ME/CFS: a perspective
Tomas, C., & Elson, J. L. (2019) · Fatigue Biomedicine Health & Behavior · doi:10.1080/21641846.2019.1580855 · Cited by 9
Engineering Genetic Systems for Treating Mitochondrial Diseases
Jang, Y., Ahn, S. R., Shim, J.-Y., & Lim, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060810 · Cited by 9
“Hundreds of mutations at different mtDNA sites have been reported to reduce the expression of the functional gene products required for oxidative phosphorylation [4].”
BackgroundKorzeniewski, B. (2021) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00196.2021 · Cited by 9
Functional effects of mutations in cytochrome c oxidase related to prostate cancer
Namslauer, I., Dietz, M. S., & Brzezinski, P. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.02.005 · Cited by 9
Toward a mtDNA locus-specific mutation database using the LOVD platform
Elson, J. L., Sweeney, M. G., Procaccio, V., et al. (2012) · Human Mutation · doi:10.1002/humu.22118 · Cited by 9
Self-citationKorzeniewski, B. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00358.2016 · Cited by 9
“Finally, the tissue differences in relative OXPHOS complex amounts/activities are important only for the tissue specificity of mitochondrial diseases related to mutations in particular complex subunit-encoding genes, while the majority of mitochondrial diseases are caused by the entire OXPHOS deficiencies related to m…”
BackgroundA systematic review on the biochemical threshold of mitochondrial genetic variantsPreprint
Smith, K. K., Moreira, J. D., Wilson, C. R., Padera, J. O., Lamason, A. N., Xue, L., Gopal, D. M., Flynn, D., & Fetterman, J. L. (2024) · Genome Research · doi:10.1101/gr.278200.123 · Cited by 10
“Prior studies have suggested that the phenotypic and bio-chemical thresholds of mitochondrial disease – causing variants are at VAFs of ≥ 60% (Tuppen et al. 2010).”
BackgroundMitochondrial DNA maintenance in Drosophila melanogaster
Rodrigues, A. P., Novaes, A. C., Ciesielski, G. L., & Oliveira, M. T. (2022) · Bioscience Reports · doi:10.1042/bsr20211693 · Cited by 9
“The mixture of wild-type and mutated mtDNA molecules in a single individual is referred to as heteroplasmy, and is an integral part of our understanding of mtDNA diseases, as the proportion of mutated molecules in a cell/tissue type of a person dictates manifestation of disease symptoms [6,7].”
Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma
Zhan, Z., Lin, K., & Wang, T. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03441-6 · Cited by 8
“In the process of biological oxidation, substrate dehy-drogenation produces NADH and FMNH2, which are oxidized through the respiratory chain to generate water [9, 10].”
BackgroundAre Mitochondria a Potential Target for Treating β-Thalassemia?
Pierro, E. D., Stefano, V. D., Amicis, M. M. D., & Graziadei, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041095 · Cited by 8
“…or nDNA that affect mitochondrial function can lead to various inherited diseases, such as Leber’s hereditary optic neuropathy (LHON), Kearns–Sayre syndrome (KSS), mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), mitochondrial myopathy, and Leigh syndrome [50,51].”
Ragab, M., Schlichting, H., Hicken, M., Mester, P., Hirose, M., de Almeida, L. N., Christiansen, L., Ibrahim, S. M., Tews, H. C., Divanovic, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63730-4 · Cited by 8
Hefti, E., Bard, J., & Blanco, J. G. (2016) · Human Mutation · doi:10.1002/humu.23071 · Cited by 8
Delivery of mtZFNs into Early Mouse Embryos
McCann, B. J., Cox, A. L., Gammage, P. A., et al. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8799-3_16 · Cited by 8
Pham, V. H., Nguyen, L. V., Jung, H., Cho, Y., & Shin, J. (2022) · BMC Medical Genomics · doi:10.1186/s12920-021-01153-0 · Cited by 8
“The polymorphism of mitochondrial genome has been shown to be associated with v arious pathophysiological conditions, and could play a role in various physiological and pathological characteristics [3].”
BackgroundModulating Mitochondrial DNA Heteroplasmy with Mitochondrially Targeted Endonucleases
Mikhailov, N., & Hämäläinen, R. H. (2022) · Annals of Biomedical Engineering · doi:10.1007/s10439-022-03051-7 · Cited by 9
“…of human disease-causing mtDNA mutations were reported in 1988 30,70 and to date, more than 250 pathogenic mtDNA mutations have been identified 68 The limited ability of mtDNA to self-re-pair, high mutation rate of the mitochondrial genome, generation of reactive oxygen species (ROS) during…”
BackgroundIn Utero Exposure to Air Pollutants and Mitochondrial Heteroplasmy in Neonates.
Cosemans, C., Wang, C.-R., Martens, D., Janssen, B., Vanpoucke, C., Lefebvre, W., Smeets, K., Nawrot, T., & Plusquin, M. (2022) · Environmental Science and Technology · doi:10.1021/acs.est.2c02556 · Cited by 9
Disease-associated mitochondrial mutations and the evolution of primate mitogenomes
Tavares, W. C., & Seuánez, H. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177403 · Cited by 10
A Novel Mitochondrial DNA Deletion in Patient with Pearson Syndrome
Khasawneh, R. H., Alsokhni, H., Al-Zghoul, B., Momani, A., Abualsheikh, N., Kamal, N., & Qatawneh, M. (2018) · Medical Archives · doi:10.5455/medarh.2018.72.148-150 · Cited by 10
“There are many clinical syndromes result from mtDNA mutations which can be classified according to the age of presentation into: early onset (infancy/childhood) like Pearson syndrome and Kearns-Sayre syndrome, and late onset (late childhood or adulthood) like chronic progressive external ophthalmoplasia (8, 10).”
BackgroundInfluentialA mitochondria-selective near-infrared-emitting fluorescent dye for cellular imaging studies
Choi, P. J., Noguchi, K., Ishiyama, M., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.001 · Cited by 8
A high prevalence of arterial hypertension in patients with mitochondrial diseases
Chong-Nguyen, C., Stalens, C., Goursot, Y., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12195 · Cited by 8
“005 LV systolic dysfunction 10 (4) 5 (3) 5 (5) .”
Natural and Artificial Mechanisms of Mitochondrial Genome Elimination
Zakirova, E. G., Muzyka, V. V., Mazunin, I., & Orishchenko, К. E. (2021) · Life · doi:10.3390/life11020076 · Cited by 9
“dition to the tissue specificity of the heteroplasmy threshold level, it also depends on whether it is a point mutation (average critical level >80%) or a deletion (>60%) [27,28].”
BackgroundKargaran, P. K., Mosqueira, D., & Kozicz, T. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.604581 · Cited by 8
“While over 250 distinct disease-causing variants have been identified in mtDNA (24), the most common point mutation”
BackgroundEffects of Ageing on the Mitochondrial Genome in Rat Vestibular Organs
Bigland, M. J., Brichta, A. M., & Smith, D. W. (2019) · Current Aging Science · doi:10.2174/1874609811666180830143358 · Cited by 8
“The proximity of mtDNA to the sites of ROS production likely contributes to the mutation frequency in the mitochondrial genome being up to 17 times greater than in the nuclear genome [20, 21].”
O’Keefe, H., Queen, R. A., Lord, P., & Elson, J. L. (2019) · Evolutionary Applications · doi:10.1111/eva.12851 · Cited by 7
Meldau, S., Riordan, G. T., van der Westhuizen, F. H., et al. (2016) · South African Medical Journal · doi:10.7196/samj.2016.v106i3.10170 · Cited by 8
Mechanisms and disease relevance of mitochondrial translation in humans
Richter‐Dennerlein, R., Dopico, X. C., & Rorbach, J. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-026-00948-2 · Cited by 10
“So far, >300 of such mutations have been identified (reviewed previously 74–76 ).”
An Introduction to Mitochondria, Their Structure and Functions
Simcox, E. M., & Reeve, A. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-28637-2_1 · Cited by 7
Recruitment of the Antiporter Module – A Key Event in Complex I Evolution
Moparthi, V. K., & Hägerhäll, C. (2012) · Springer eBooks · doi:10.1007/978-94-007-4138-6_7 · Cited by 7
Intramitochondrial transfer and engineering of mammalian mitochondrial genomes in yeast
Yoon, Y. G., & Koob, M. D. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.03.006 · Cited by 7
Metadata
- Authors
- Tuppen, H. A. L., Blakely, E. L., Turnbull, D. M., & Taylor, R. W.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Taylor, Robert W.
- Venue
- Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 1797
- Issue
- 2
- Pages
- 113-128
- ISSN
- 0005-2728 (ISSN-L)
- OpenAlex
- W1997422422
- Semantic Scholar
- b52cea89f7d29e4137fb6e7175963cf0d992f736
- Cited by
- 676
- References
- 272
- Citations by year
- 2026: 19 · 2025: 34 · 2024: 41 · 2023: 32 · 2022: 35 · 2021: 50 · 2020: 51 · 2019: 46 · 2018: 81 · 2017: 44 · 2016: 49 · 2015: 32 · 2014: 24 · 2013: 33 · 2012: 38
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Biochimica et Biophysica Acta (BBA) - Bioenergetics (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (074454)
- Sparks
- Muscular Dystrophy UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- mitochondrial DNA mutations, mitochondrial disease, oxidative phosphorylation defects, mitochondrial genetics, nuclear-encoded mitochondrial proteins, mitochondrial disease diagnosis, mitochondrial disease therapy, disease models
- MeSH terms
- DNA, Mitochondrial, Humans, Mutation, Mitochondrial Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review